441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Shareholder votes
Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid's OV329 Shows Strong Inhibitory Activity & Best-in-Category Safety
Other Events
Reports Business Updates and Second Quarter 2025 Financial Results
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
PREM14A
Correspondence
Submission Upload
S-8 POS